NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.1600
+0.1000 (166.67%)
Apr 13, 2026, 10:01 AM EST
NKGen Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
7.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
| Dec 31, 2021 | 426.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNKGen Biotech News
- 6 days ago - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - GlobeNewsWire
- 23 days ago - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ - GlobeNewsWire
- 5 weeks ago - NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026 - GlobeNewsWire
- 2 months ago - NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. - GlobeNewsWire
- 6 months ago - NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - GlobeNewsWire
- 6 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - GlobeNewsWire
- 7 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum - GlobeNewsWire
- 7 months ago - NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - GlobeNewsWire